Non Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Evaluation of Efficacy and Safety of Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
Verified date | January 2020 |
Source | Ain Shams University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to evaluate the efficacy and safety of Niacinamide supplementation on clinical outcome of fatty liver patients having type II DM through measurement of the following before and after Niacinamide administration: Liver enzymes, Lipid profie, HOMA-IR, Oxidative stress markers and endothelial dysfunction marker. Fibroscan with CAP will be done at baseline and at the end of the trial. Also, Evaluation of quality of life of patients before and after Niacinamide administration using Chronic Liver Disease questionnaire.
Status | Completed |
Enrollment | 61 |
Est. completion date | August 7, 2019 |
Est. primary completion date | August 7, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - 1. Male or female outpatients age 18 to 70 years old. 2. The diagnosis of NAFLD will be established according to the appearance of fatty liver on US or elevated liver enzymes (>1.5 times normal level). Exclusion Criteria: - 1. History of alcohol abuse (as defined by an average daily consumption of alcohol > 30 g/day in men and > 20 g/day in women). 2. Cirrhotic patients. - Fibroscan result > 12Kpa or as - predicted from FIB 4 score > 3.25 FIB-4 = age (yr) * AST (IU/L)/platelet count (109/L) * ALT1/2 (IU/L) 3. Hyper / hypoparathyroidism. 4. Cancer. 5. Viral hepatitis. 6. Biliary disease. 7. Autoimmune hepatitis 8. Other causes of liver disease (hemochromatosis, Wilson's disease). 9. Participants who took antibiotics, probiotic supplements and/or hepatotoxic medicines (NSAIDs, Amiodarone and methotrexate) within 6 months before the start of the study and during the study. 10. Ascetic patients and congestive heart failure patients will be excluded due to unreliability of Fibroscan results in them. 11. Pregnancy and lactation. |
Country | Name | City | State |
---|---|---|---|
Egypt | AlZahraa hospital | Cairo |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Chronic Liver Disease Questionnaire | quality of measurement | 3 months | |
Primary | Steatosis using Fibroscan with CAP | using Fibroscan with CAP | 3 months | |
Primary | Adiponectin mesurement | Endothelial dysfunction | 3 months | |
Secondary | Malondialdehyde | Oxidative stress marker | 3 monthes | |
Secondary | HOMA-IR | Insulin resistance | 3 months | |
Secondary | ALT, AST | Liver enzymes | 3 months | |
Secondary | LDL, cholesterol | Lipid markers | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
Completed |
NCT01277237 -
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT04442620 -
Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity
|
N/A | |
Completed |
NCT01999101 -
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
|
Phase 2 | |
Completed |
NCT01327443 -
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
|
N/A | |
Active, not recruiting |
NCT01482065 -
The Sleep, Liver Evaluation and Effective Pressure Study
|
N/A | |
Completed |
NCT03135873 -
Mastiha Treatment for Obese With NAFLD Diagnosis
|
N/A | |
Completed |
NCT02686476 -
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT02820285 -
Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
|
N/A | |
Completed |
NCT01556113 -
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
|
N/A | |
Recruiting |
NCT06080386 -
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
|
||
Terminated |
NCT02134522 -
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
|
N/A | |
Completed |
NCT01553500 -
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT05426382 -
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT03300661 -
Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine
|
N/A | |
Not yet recruiting |
NCT02178839 -
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
|
N/A | |
Recruiting |
NCT02038387 -
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
|
N/A | |
Completed |
NCT01634048 -
The Effect of Protein-enriched Diet on Body Composition and Appetite
|
N/A | |
Completed |
NCT01874249 -
Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease
|
N/A | |
Completed |
NCT01966627 -
Genetics of Fatty Liver Disease in Children
|
N/A |